FDA to Streamline Approval of Drugs for Rare Diseases & Custom Therapies

Federal health officials on February 23, 2026, announced a proposed framework to accelerate the development of customized treatments for patients with difficult-to-treat diseases, particularly rare genetic conditions that have historically been considered commercially unviable for pharmaceutical companies. The new pathway, unveiled by the U.S. Food and Drug Administration (FDA), aims to streamline the approval process for individualized therapies, including gene editing and RNA-based treatments, when traditional clinical trials are not feasible due to small patient populations.

The proposed guidelines represent a significant shift in regulatory thinking, responding to long-standing calls from patients, advocates, and researchers focused on rare diseases. These conditions often don’t align with the conventional pharmaceutical business model or the FDA’s traditional drug approval system. “It is our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases,” stated FDA Commissioner Marty Makary in a press release.

This announcement follows a recent decision by the FDA to drop its decades-old standard of requiring two independent clinical trials for standard drug reviews. While officials emphasize that these changes do not constitute new FDA standards, they signal a broader effort to adapt the agency’s approach to emerging scientific advancements and the unique challenges of developing therapies for ultra-rare conditions. The FDA will accept public comments on the draft guidance for 60 days before finalizing it.

The core of the new pathway centers around the concept of a “plausible mechanism.” FDA officials will require evidence demonstrating a clear understanding of the disease and a biologically plausible reason to believe the therapy will address the underlying genetic or cellular abnormality. Researchers will also need to confirm that the therapy successfully targets the specific abnormality in each patient.

For years, academic researchers have been pioneering the development of personalized therapies using technologies like CRISPR gene editing. In May 2025, a team at Children’s Hospital of Philadelphia and the University of Pennsylvania successfully designed a CRISPR-based therapy to treat an infant born with a rare genetic disorder causing dangerous ammonia buildup in the blood. These advancements highlight the potential of tailored treatments, but also underscore the need for a regulatory framework that can accommodate the unique challenges of small-scale development and clinical evaluation.

Traditionally, the FDA requires pharmaceutical companies to demonstrate the safety and efficacy of new treatments through large-scale, randomized controlled trials. These trials compare a group of patients receiving the therapy to a control group receiving a placebo or standard treatment. However, for diseases affecting only a tiny fraction of the global population, conducting such trials is often impractical and financially prohibitive. Drug companies may lack the incentive to invest the substantial resources required to complete a study and navigate the lengthy FDA approval process, which can take a decade or more.

The proposed pathway aims to address this challenge by creating a standardized process for authorizing experimental treatments and, crucially, offering companies a pathway to commercialization. Currently, the FDA allows access to experimental drugs through “compassionate use” programs for patients with no other options. However, this process is complex and prohibits companies from profiting from unapproved therapies.

The FDA’s focus on therapies that target a specific genetic, cellular, or molecular abnormality is key. The agency will prioritize treatments that directly address the root cause of the disease, rather than simply managing symptoms. Key criteria for approval will include identifying the disease-causing abnormality, demonstrating that the therapy targets the underlying cause or a closely related biological pathway, and relying on well-characterized natural history data from untreated patients. Confirmation that the therapy successfully engages the intended target—what regulators call “successful target drugging or editing”—will also be essential.

This new approach builds upon existing FDA authorities and does not currently require new legislation. As a former Director of the FDA’s Center for Drug Evaluation and Research cautioned, the traditional randomized controlled trial and statistical significance thresholds may not be “fit for purpose” when evaluating treatments for rare diseases in small trials. The FDA’s move reflects a growing recognition that a more flexible and adaptable regulatory approach is needed to unlock the potential of personalized medicine and deliver hope to patients with ultra-rare conditions.